Titre : Chimiokine CCL2

Chimiokine CCL2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Implementation Science
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Chimiokine CCL2 : Questions médicales les plus fréquentes", "headline": "Chimiokine CCL2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Chimiokine CCL2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-26", "dateModified": "2025-02-20", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Chimiokine CCL2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines chimioattractives monocytaires", "url": "https://questionsmedicales.fr/mesh/D018945", "about": { "@type": "MedicalCondition", "name": "Protéines chimioattractives monocytaires", "code": { "@type": "MedicalCode", "code": "D018945", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.110.990" } } }, "about": { "@type": "MedicalCondition", "name": "Chimiokine CCL2", "alternateName": "Chemokine CCL2", "code": { "@type": "MedicalCode", "code": "D018932", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Nidhi Joshi", "url": "https://questionsmedicales.fr/author/Nidhi%20Joshi", "affiliation": { "@type": "Organization", "name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India." } }, { "@type": "Person", "name": "Krishna Mohan Poluri", "url": "https://questionsmedicales.fr/author/Krishna%20Mohan%20Poluri", "affiliation": { "@type": "Organization", "name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India. Electronic address: krishfbt@iitr.ac.in." } }, { "@type": "Person", "name": "Nupur Nagar", "url": "https://questionsmedicales.fr/author/Nupur%20Nagar", "affiliation": { "@type": "Organization", "name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India." } }, { "@type": "Person", "name": "Élora Midavaine", "url": "https://questionsmedicales.fr/author/%C3%89lora%20Midavaine", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca." } }, { "@type": "Person", "name": "Philippe Sarret", "url": "https://questionsmedicales.fr/author/Philippe%20Sarret", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Integration of implementation science in cardiovascular behavioral medicine.", "datePublished": "2022-08-11", "url": "https://questionsmedicales.fr/article/35951404", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1037/hea0001208" } }, { "@type": "ScholarlyArticle", "name": "Application of dissemination and implementation science frameworks to surgical research.", "datePublished": "2022-10-12", "url": "https://questionsmedicales.fr/article/36414362", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1053/j.semvascsurg.2022.10.001" } }, { "@type": "ScholarlyArticle", "name": "Quality, safety, and implementation science in acute kidney care.", "datePublished": "2022-10-11", "url": "https://questionsmedicales.fr/article/36226720", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MCC.0000000000000999" } }, { "@type": "ScholarlyArticle", "name": "Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37213606", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2023.1172557" } }, { "@type": "ScholarlyArticle", "name": "Advancing healthcare equity through dissemination and implementation science.", "datePublished": "2023-05-23", "url": "https://questionsmedicales.fr/article/37219339", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1475-6773.14175" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Chimiokines", "item": "https://questionsmedicales.fr/mesh/D018925" }, { "@type": "ListItem", "position": 6, "name": "Chimiokines CC", "item": "https://questionsmedicales.fr/mesh/D019742" }, { "@type": "ListItem", "position": 7, "name": "Protéines chimioattractives monocytaires", "item": "https://questionsmedicales.fr/mesh/D018945" }, { "@type": "ListItem", "position": 8, "name": "Chimiokine CCL2", "item": "https://questionsmedicales.fr/mesh/D018932" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Chimiokine CCL2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Chimiokine CCL2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Chimiokine CCL2", "description": "Comment mesurer les niveaux de CCL2 ?\nQuels tests sont utilisés pour évaluer l'inflammation ?\nCCL2 est-il un biomarqueur de maladies ?\nComment CCL2 est-il lié à la maladie cardiovasculaire ?\nPeut-on détecter CCL2 dans le liquide céphalorachidien ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Implementation+Science&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Chimiokine CCL2", "description": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?\nCCL2 est-il lié à des symptômes neurologiques ?\nComment CCL2 affecte-t-il le système immunitaire ?\nDes niveaux de CCL2 peuvent-ils causer de la douleur ?\nCCL2 est-il impliqué dans des maladies respiratoires ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Implementation+Science&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Chimiokine CCL2", "description": "Comment réduire les niveaux de CCL2 ?\nLe stress influence-t-il CCL2 ?\nY a-t-il des aliments qui réduisent CCL2 ?\nL'exercice physique affecte-t-il CCL2 ?\nLa qualité du sommeil influence-t-elle CCL2 ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Implementation+Science&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Chimiokine CCL2", "description": "Quels traitements ciblent CCL2 ?\nCCL2 peut-il être une cible pour des thérapies anticancéreuses ?\nComment les anti-inflammatoires affectent-ils CCL2 ?\nY a-t-il des traitements naturels pour CCL2 ?\nLes corticostéroïdes influencent-ils CCL2 ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Implementation+Science&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Chimiokine CCL2", "description": "Quelles complications sont liées à CCL2 ?\nCCL2 est-il impliqué dans des maladies neurodégénératives ?\nComment CCL2 affecte-t-il le diabète ?\nY a-t-il des risques d'infection liés à CCL2 ?\nCCL2 est-il lié à des troubles auto-immuns ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Implementation+Science&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Chimiokine CCL2", "description": "Quels facteurs augmentent CCL2 ?\nL'âge influence-t-il les niveaux de CCL2 ?\nLes infections chroniques affectent-elles CCL2 ?\nLe régime alimentaire influence-t-il CCL2 ?\nLe manque d'exercice est-il un facteur de risque pour CCL2 ?", "url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Implementation+Science&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer les niveaux de CCL2 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de CCL2 peuvent être mesurés par des tests ELISA dans le sérum ou les tissus." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'inflammation ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests comme la CRP et la mesure de CCL2 aident à évaluer l'inflammation." } }, { "@type": "Question", "name": "CCL2 est-il un biomarqueur de maladies ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est un biomarqueur potentiel pour des maladies inflammatoires et auto-immunes." } }, { "@type": "Question", "name": "Comment CCL2 est-il lié à la maladie cardiovasculaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de CCL2 sont associés à l'inflammation dans les maladies cardiovasculaires." } }, { "@type": "Question", "name": "Peut-on détecter CCL2 dans le liquide céphalorachidien ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 peut être détecté dans le liquide céphalorachidien, indiquant une inflammation neurologique." } }, { "@type": "Question", "name": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de CCL2 peuvent entraîner des symptômes d'inflammation comme douleur et fatigue." } }, { "@type": "Question", "name": "CCL2 est-il lié à des symptômes neurologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est impliqué dans des symptômes neurologiques dans des maladies comme la sclérose en plaques." } }, { "@type": "Question", "name": "Comment CCL2 affecte-t-il le système immunitaire ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "CCL2 attire les monocytes et les lymphocytes, influençant la réponse immunitaire." } }, { "@type": "Question", "name": "Des niveaux de CCL2 peuvent-ils causer de la douleur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 peut contribuer à la douleur en favorisant l'inflammation dans les tissus." } }, { "@type": "Question", "name": "CCL2 est-il impliqué dans des maladies respiratoires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est associé à des maladies respiratoires comme l'asthme et la BPCO." } }, { "@type": "Question", "name": "Comment réduire les niveaux de CCL2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain, avec une alimentation équilibrée et de l'exercice, peut aider." } }, { "@type": "Question", "name": "Le stress influence-t-il CCL2 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter les niveaux de CCL2 et l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il des aliments qui réduisent CCL2 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des aliments riches en antioxydants, comme les baies, peuvent aider à réduire CCL2." } }, { "@type": "Question", "name": "L'exercice physique affecte-t-il CCL2 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut diminuer les niveaux de CCL2 et améliorer la santé globale." } }, { "@type": "Question", "name": "La qualité du sommeil influence-t-elle CCL2 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un sommeil de qualité peut réduire l'inflammation et les niveaux de CCL2 dans le corps." } }, { "@type": "Question", "name": "Quels traitements ciblent CCL2 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de CCL2 sont en développement pour traiter des maladies inflammatoires." } }, { "@type": "Question", "name": "CCL2 peut-il être une cible pour des thérapies anticancéreuses ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, cibler CCL2 pourrait aider à réduire l'infiltration tumorale et l'inflammation." } }, { "@type": "Question", "name": "Comment les anti-inflammatoires affectent-ils CCL2 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les anti-inflammatoires peuvent réduire les niveaux de CCL2 et atténuer l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour CCL2 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent moduler les niveaux de CCL2, mais des études sont nécessaires." } }, { "@type": "Question", "name": "Les corticostéroïdes influencent-ils CCL2 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent réduire l'expression de CCL2 dans les tissus inflammés." } }, { "@type": "Question", "name": "Quelles complications sont liées à CCL2 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de CCL2 peuvent entraîner des complications dans les maladies cardiovasculaires." } }, { "@type": "Question", "name": "CCL2 est-il impliqué dans des maladies neurodégénératives ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est associé à des complications dans des maladies comme Alzheimer et Parkinson." } }, { "@type": "Question", "name": "Comment CCL2 affecte-t-il le diabète ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "CCL2 peut contribuer à l'inflammation et aux complications associées au diabète." } }, { "@type": "Question", "name": "Y a-t-il des risques d'infection liés à CCL2 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de CCL2 peuvent augmenter le risque d'infections en favorisant l'inflammation." } }, { "@type": "Question", "name": "CCL2 est-il lié à des troubles auto-immuns ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CCL2 est impliqué dans des complications de troubles auto-immuns comme la polyarthrite." } }, { "@type": "Question", "name": "Quels facteurs augmentent CCL2 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme, l'obésité et le stress sont des facteurs de risque augmentant CCL2." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux de CCL2 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de CCL2 tendent à augmenter avec l'âge, contribuant à l'inflammation." } }, { "@type": "Question", "name": "Les infections chroniques affectent-elles CCL2 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections chroniques peuvent augmenter les niveaux de CCL2 dans le corps." } }, { "@type": "Question", "name": "Le régime alimentaire influence-t-il CCL2 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Un régime riche en graisses saturées peut augmenter les niveaux de CCL2 et l'inflammation." } }, { "@type": "Question", "name": "Le manque d'exercice est-il un facteur de risque pour CCL2 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le manque d'exercice peut contribuer à des niveaux élevés de CCL2 et à l'inflammation." } } ] } ] }

Sources (10000 au total)

Quality, safety, and implementation science in acute kidney care.

Quality and safety are important themes in acute kidney care (AKC). There have been many recent initiatives highlighting these aspects. However, for these to become part of clinical practice, a rigoro... The 22nd Acute Disease Quality Initiative (ADQI) focused on achieving a framework for improving AKI care. This has led to various quality improvement (QI) initiatives that have been implemented follow... Quality and safety continue to be important focuses in AKC. Although recent work have focused on initiatives to improve these themes, additional work is necessary to further develop these items as we ...

Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities.

The purpose of developing and adopting regulatory science (RS) for drug regulatory authorities (DRAs) is to enhance regulatory capacity by advancing the scientific approach for the evaluation of healt... Documentary analysis of government documents and a scoping literature review were conducted, and data analysis was performed under the guidance of the PRECEDE-PROCEED Model (PPM). DRAs in the United S... There is no common consensus on the definition of RS among the DRAs. However, these DRAs shared the same goal of developing and adopting RS, which was used to develop new tools, standards, and guideli... The application of the implementation science framework is useful for conceptualizing and planning the development and adoption of RS for evidence-based regulatory decision-making. Continuous commitme...

Advancing healthcare equity through dissemination and implementation science.

To provide guiding principles and recommendations for how approaches from the field of dissemination and implementation (D&I) science can advance healthcare equity.... This article, part of a special issue sponsored by the Agency for Healthcare Research and Quality (AHRQ), is based on an outline drafted to support proceedings of the 2022 AHRQ Health Equity Summit an... This is a narrative review of the current and potential applications of D&I approaches for understanding and advancing healthcare equity, followed by discussion and feedback with Summit attendees.... We identified major themes in narrative and systematic reviews related to D&I science, healthcare equity, and their intersections. Based on our expertise, and supported by synthesis of published studi... We identified four guiding principles and three D&I science domains with strong promise for accelerating progress toward healthcare equity. We present eight recommendations and more than 60 opportunit... Promising areas for D&I science to impact healthcare equity include the following: attention to equity in the development and delivery of evidence-based interventions; the science of adaptation; de-im...

Aligning organisational priorities and implementation science for cancer research.

The challenge of implementing evidence into routine clinical practice is well recognised and implementation science offers theories, models and frameworks to promote investigation into delivery of evi... We undertook a qualitative study using semi-structured interviews. Participants held either a formal leadership role, were research active or a consumer advocate and affiliated with either a specialis... Thirty-one people participated between August 2022 and February 2023. Four themes were identified: 1) Integration of services to address organisational priorities e.g., tackling fragmented services; 2... Using a theory informed and structured approach the alignment between strategic organisational priorities and implementation research priorities can be identified. As a result, the implementation rese...

Implementation Science Research in Pediatric Critical Care Medicine.

Delay or failure to consistently adopt evidence-based or consensus-based best practices into routine clinical care is common, including for patients in the PICU. PICU patients can fail to receive pote... The members of Excellence in Pediatric Implementation Science (ECLIPSE; part of the Pediatric Acute Lung Injury and Sepsis Investigators Network) represent multi-institutional expertise in the use of ... IS requires a shift in one's thinking, away from questions and outcomes that define traditional clinical or translational research, including QI. Instead, in the IS rather than the QI literature, the ... Research in pediatric critical care practice must acknowledge the limitations and potential for patient harm that may result from a failure to implement evidence-based or professionals' consensus-base...

Elaboration and implementation of a protocol for the Golden Hour of premature newborns using an Implementation Science lens.

describe the process of designing and implementing a care protocol for the first hour of life of premature newborns.... a participatory research study using an implementation science framework, the Consolidated Framework for Implementation Research (CFIR) was employed to determine drivers and facilitators of implementa... the institution's Golden Hour protocol was organized by the multi-professional team based on a collective and dialogical approach. The protocol prioritized the infant's cardiopulmonary stability, as w... implementation of the Golden Hour protocol introduced an appropriate and feasible neonatal care quality improvement process, which requires periodic refresher training to ensure greater adherence and ...

Implementation Science Perspectives on Implementing Telemedicine Interventions for Hypertension or Diabetes Management: Scoping Review.

Hypertension and diabetes are becoming increasingly prevalent worldwide. Telemedicine is an accessible and cost-effective means of supporting hypertension and diabetes management, especially as the CO... We adopted a comprehensive implementation research perspective to synthesize the barriers to and facilitators of implementing telemedicine interventions for the management of hypertension, diabetes, o... We performed a scoping review involving searches in Ovid MEDLINE, Embase, CINAHL, Cochrane Library, Web of Science, and Google Scholar to identify studies published in English from 2017 to 2022 descri... Of the 17,687 records identified, 35 (0.2%) studies were included in our scoping review. We found that facilitators of and barriers to implementation were dispersed across the constructs of the Consol... Our findings suggest that the successful implementation of telemedicine interventions for hypertension and diabetes requires comprehensive efforts at the planning, execution, engagement, and reflectio...